Overview
Revel Pharmaceuticals is a biopharmaceutical company developing engineered enzyme therapeutics to reverse age-related molecular damage in structural tissues. The company targets fundamental hallmarks of aging, particularly glycation and collagen crosslinking, which underlie multiple age-related diseases, including osteoarthritis, cardiovascular disease, diabetes complications, and skin aging. Revel's platform identifies and optimizes naturally occurring enzymes to repair specific forms of protein damage, positioning the company to address the root causes of aging-related pathology rather than managing symptoms alone. The company's lead program, CMLase, demonstrated enzymatic reversal of carboxymethyl-lysine (CML) accumulation in human tissue, a form of damage previously considered irreversible for over four decades.